98 related articles for article (PubMed ID: 21479474)
1. Serum thymidine kinase 1 reflects the progression of pre-malignant and malignant tumors during therapy.
Xu XH; Zhang YM; Shu XH; Shan LH; Wang ZW; Zhou YL; Wen HK; He F; He E; Skog S
Mol Med Rep; 2008; 1(5):705-11. PubMed ID: 21479474
[TBL] [Abstract][Full Text] [Related]
2. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients.
Zhang J; Jia Q; Zou S; Zhang P; Zhang X; Skog S; Luo P; Zhang W; He Q
Oncol Rep; 2006 Feb; 15(2):455-61. PubMed ID: 16391869
[TBL] [Abstract][Full Text] [Related]
3. Serological thymidine kinase 1 is a biomarker for early detection of tumours--a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay.
Chen ZH; Huang SQ; Wang Y; Yang AZ; Wen J; Xu XH; Chen Y; Chen QB; Wang YH; He E; Zhou J; Skog S
Sensors (Basel); 2011; 11(12):11064-80. PubMed ID: 22247653
[TBL] [Abstract][Full Text] [Related]
4. Transient increase in serum thymidine kinase 1 within one week after surgery of patients with carcinoma.
Li Z; Wang Y; Ma J; He J; Zhou J; He E; Skog S
Anticancer Res; 2010 Apr; 30(4):1295-9. PubMed ID: 20530443
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression.
Huang S; Lin J; Guo N; Zhang M; Yun X; Liu S; Zhou J; He E; Skog S
Asian Pac J Cancer Prev; 2011; 12(2):497-505. PubMed ID: 21545220
[TBL] [Abstract][Full Text] [Related]
6. Serological thymidine kinase 1 (STK1) indicates an elevated risk for the development of malignant tumours.
Chen Z; Zhou H; Li S; He E; Hu J; Zhou J; Skog S
Anticancer Res; 2008; 28(6B):3897-907. PubMed ID: 19192647
[TBL] [Abstract][Full Text] [Related]
7. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer.
Li HX; Lei DS; Wang XQ; Skog S; He Q
Oncol Rep; 2005 Jan; 13(1):145-9. PubMed ID: 15583816
[TBL] [Abstract][Full Text] [Related]
8. [Application of serum thymidine kinase 1 of 26 055 cases in health screening for early detection of premalignant/early malignant tumors].
Cao X; Wang Y; Yang P; Zhou H; Liu C; Chen Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Oct; 39(10):1029-34. PubMed ID: 25355255
[TBL] [Abstract][Full Text] [Related]
9. Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas.
Li Z; Wang Y; He J; Ma J; Zhao L; Chen H; Li N; Zhou J; He E; Skog S
Eur J Cancer Prev; 2010 Jul; 19(4):313-8. PubMed ID: 20479645
[TBL] [Abstract][Full Text] [Related]
10. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings.
Chen Y; Ying M; Chen Y; Hu M; Lin Y; Chen D; Li X; Zhang M; Yun X; Zhou J; He E; Skog S
Int J Clin Oncol; 2010 Aug; 15(4):359-68. PubMed ID: 20354751
[TBL] [Abstract][Full Text] [Related]
11. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.
Luo P; He E; Eriksson S; Zhou J; Hu G; Zhang J; Skog S
Eur J Cancer Prev; 2009 Jun; 18(3):220-4. PubMed ID: 19282758
[TBL] [Abstract][Full Text] [Related]
12. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.
Jagarlamudi KK; Hansson LO; Eriksson S
BMC Cancer; 2015 Feb; 15():66. PubMed ID: 25881026
[TBL] [Abstract][Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
14. The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer.
Zou L; Zhang PG; Zou S; Li Y; He Q
Int J Biol Markers; 2002; 17(2):135-40. PubMed ID: 12113581
[TBL] [Abstract][Full Text] [Related]
15. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.
Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I
Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350
[TBL] [Abstract][Full Text] [Related]
17. Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer.
Liu Y; Ling Y; Qi Q; Tang Y; Xu J; Tong Z; Sheng G; Yang Q; Pan Y
Exp Ther Med; 2011 Nov; 2(6):1177-1181. PubMed ID: 22977640
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
20. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
